肿瘤药学2019，Vol.9Issue(5)：789-792,4.DOI:10.3969/j.issn.2095-1264.2019.05.18
吉西他滨膀胱灌注在膀胱癌患者中的疗效观察及对生存期的影响研究★
Effect of Gemcitabine Intravesical Instillation in Patients with Bladder Cancer and Its Influence on Survival★
摘要
Abstract
Objective To investigate the efficacy of gemcitabine intravesical instillation in patients with bladder cancer and its effect on survival. Methods A total of 110 patients with bladder cancer admitted to our hospital between August 2015 and August 2017 were se-lected as the study subjects. They were randomly divided into control group and observation group, 55 in each group. The control group was treated with 30 mg pirarubicin + 50 mL 5% glucose solution for bladder perfusion, while the observation group was treated with 1000 mg gemcitabine + 50 mL saline for intravesical drugs. Perfusion chemotherapy was given once a week for 8 consecutive times, thereafter, once a month for one year. Cystoscopy and routine examination were repeated every 3 months. All patients were followed up for two years. During the follow-up period, the recurrence time, recurrence progression time and adverse reactions were recorded in detail. Urine samples were taken from patients before treatment and at 3 months after treatment. The expression levels of nuclear matrix protein 22 (NMP-22), bladder cancer specific nuclear matrix protein 4 (BLCA-4), interleukin-8 (IL-8) were detected by ELISA kit. Results Compared with the control group, there was no significant difference in 1-year recurrence rate and 2-year cumulative recurrence rate in the observation group (P>0.05). But the non-recurrence survival time of the observation group was significantly longer than that of the control group (P<0.05). Compared with before treatment, the urinary tumor markers in the control group and the observation group were significantly lowered after treatment (P<0.05). Compared with the control group, the urine NMP-22 level was decreased in the observation group, but there was no significant difference (P>0.05). The levels of BLCA-4 and IL-8 were significantly lower in the observation group than in the control group (P<0.05). During chemotherapy, all patients in the two groups had bladder irritation symptoms such as frequency, urgency, pain and hematuria of dif-ferent degrees. The incidence of adverse reactions was 23.36% in control group and 26.85% in observation group. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Intravesical instillation of gemcitabine in patients with bladder cancer could not only control the progress of the disease, but also have high safety. It is worthy of clinical promotion.关键词
吉西他滨/非肌层浸润性膀胱癌/疗效观察/生存期Key words
Gemcitabine/Non-muscle invasive bladder cancer/Efficacy observation/Survival time分类
医药卫生引用本文复制引用
夏浩然,梁朝朝,杨诚,陈佳..吉西他滨膀胱灌注在膀胱癌患者中的疗效观察及对生存期的影响研究★[J].肿瘤药学,2019,9(5):789-792,4.基金项目
安徽省自然科学基金(编号:1708085QH203). （编号:1708085QH203）
